What it is
Fragment 176-191 is a synthetic 16-amino-acid peptide (sequence FLRIVQCRSVEGSCGF, MW 1,799.1 Da, CAS 66004-57-7, PubChem CID 16131230) corresponding to residues 176–191 of the 191-amino-acid human growth hormone molecule. The two cysteines at positions 182 and 189 form an intramolecular disulfide bond that gives the fragment a cyclic C-terminal structure. It was originally identified by Ng, Heffernan, and colleagues at Monash University as the minimal C-terminal region of hGH that retains fat-mobilizing activity while losing the GH-receptor binding that drives IGF-1 production, hyperglycemia, and anabolism. Its closely related tyrosine-N-terminal analog, AOD-9604 (Tyr-hGH 177-191), is the form that advanced into human obesity trials; unmodified Fragment 176-191 has not been run through a registered clinical program.
In plain English
Fragment 176-191 is a lab-made chain of 16 amino acids (the building blocks of proteins). It's an exact copy of the tail piece of human growth hormone (specifically, the last 16 of 191 amino acids). Two of its amino acids are linked by a chemical bond that folds the tail into a loop. Researchers at Monash University in Australia identified it as the smallest part of growth hormone that still burns fat, while leaving behind the part that normally causes muscle growth, high blood sugar, and raised IGF-1. A closely related version with one extra amino acid on the front (AOD-9604) is the version that went into human obesity trials. Plain Fragment 176-191 has never been tested in a registered human trial.
How it works
- 01
What it is not — no growth hormone receptor engagement
The primary GH-receptor-binding epitopes of full-length hGH sit in the N-terminal and middle regions of the molecule (approximately residues 1–134). Fragment 176-191 lacks those domains, so it does not measurably bind the GH receptor and does not stimulate hepatic IGF-1 production, does not drive GHR-dependent protein synthesis, and does not reproduce the hyperglycemic / insulin-resistance signature of exogenous hGH (Heffernan 2001, Endocrinology). This receptor-independence is the peptide's defining feature and the reason it is studied at all.
In plain English
What it is NOT: it skips the growth-hormone receiver
The parts of growth hormone that normally lock onto the growth-hormone receiver sit at the front and middle of the full hormone. Fragment 176-191 is only the tail, so it doesn't attach to that receiver at all. That means it doesn't raise IGF-1 (a growth signal), doesn't push muscle growth, and doesn't cause the high-blood-sugar problem that real growth hormone causes. This "it skips the main receiver" feature is the entire reason researchers studied it in the first place.
- 02
β3-adrenergic receptor upregulation in adipose tissue
The best-characterized mechanism is indirect. Heffernan 2001 (PMID 11713213) demonstrated that chronic treatment of obese mice with AOD-9604 (the tyrosine analog of Fragment 176-191) increased β3-adrenergic receptor (ADRB3) mRNA expression in adipose tissue, restoring receptor density toward lean-mouse levels. In the same study, β3-AR knockout mice showed no weight-loss or lipolytic response to either hGH or AOD-9604, establishing that β3-AR is necessary for the effect. The fragment itself does not appear to directly bind or activate β3-AR; it increases the pool of available receptors so endogenous catecholamines produce a larger lipolytic signal.
In plain English
It puts more fat-burning receivers on fat cells
The best-understood route is indirect. In a 2001 mouse study, long-term dosing restored the number of fat-burning receivers (called β3-AR) on fat cells of obese mice back to what a lean mouse would have. Mice engineered to have no β3-AR didn't respond to the peptide at all — a strong proof that this receiver is required. The peptide itself doesn't appear to flip the receiver on directly. It increases how MANY receivers are available, so the body's natural fat-burning signals (like adrenaline) have more targets to hit.
- 03
DAG → PKC → hormone-sensitive lipase in isolated adipocytes
In vitro work in isolated rat adipocytes (Heffernan 2001 and the companion 177-191 adipocyte study from the same group) traced the downstream signal: the peptide triggers a biphasic release of diacylglycerol (DAG), DAG activates protein kinase C (PKC), and PKC phosphorylates hormone-sensitive lipase (HSL) — the rate-limiting enzyme of triglyceride hydrolysis. The fragment also modestly inhibits lipoprotein lipase (LPL), limiting new triglyceride uptake. The specific upstream receptor coupling to DAG has not been identified in peer-reviewed literature.
In plain English
The chain reaction that actually releases fat
In lab-dish work with rat fat cells, researchers traced the signal: the peptide releases a messenger called DAG, DAG turns on an enzyme called PKC, and PKC activates the enzyme (HSL) that breaks stored fat apart for burning. The peptide also slightly blocks a different enzyme (LPL) that normally packs new fat INTO fat cells. But no one has identified the very first spot on the cell that Fragment 176-191 attaches to — the whole chain was measured from the middle onward.
- 04
Obesity-dependent responsiveness
Heffernan 2001 and Ng 2001 (Int J Obesity) both reported that only obese mice, not lean mice, showed body-weight reduction and increased fat oxidation in response to the fragment. The working explanation is that obesity downregulates adipose β3-AR expression, and the fragment's mechanism corrects that suppression rather than driving lipolysis in an already-normal system. Whether this obesity-dependence translates to humans has not been tested because there are no human Fragment 176-191 trials.
In plain English
It only seems to work in obese animals
Two 2001 studies found that only obese mice responded to the peptide — lean mice did not lose weight or burn more fat. The likely reason: obesity turns down the fat-burning receivers, and the peptide turns them back up. In an already-normal body, there's nothing to fix. Nobody has tested whether this also holds in people — there are no human trials of Fragment 176-191.
- 05
What is NOT known about the mechanism
No specific high-affinity receptor for Fragment 176-191 has been identified. The plasma half-life is reported as roughly 30 minutes based on animal work, but human PK data for the unmodified fragment are absent from peer-reviewed literature. Whether repeated dosing triggers anti-drug antibodies, whether route of administration changes tissue distribution, and whether the in-vitro adipocyte signaling reproduces in human adipose tissue in vivo are all open questions. The McGuire-style theoretical cancer-biology concerns that attach to growth-factor-family peptides have not been systematically evaluated for Fragment 176-191.
In plain English
What we still don't know
No one has found the specific spot on a cell that Fragment 176-191 attaches to first. The often-quoted "about 30 minute" half-life is from animal studies — there's no peer-reviewed human data for the plain fragment. We don't know if repeated doses cause the body to build antibodies against it, whether injecting it vs. taking it another way changes where it goes in the body, or whether the lab-dish signaling actually happens in living human fat tissue. The theoretical cancer-biology concerns that apply to growth-factor peptides in general have also not been checked for this one.